Sartorius Stedim Biotech SA
Aubagne, May 4, 2021
Implementation of a new contract of liquidity with Kepler Cheuvreux
Sartorius Stedim Biotech and Kepler Cheuvreux have signed on April 29, 2021 a liquidity contract regarding the shares of Sartorius Stedim Biotech admitted to Euronext Paris (the "Agreement").
The implementation of the Agreement will be carried out in accordance with the legal provisions in force, and more specifically with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR), the delegated Commission Regulation (EU) 2016/908 of 26 February 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regulatory technical standards concerning the criteria, procedure and requirements for establishing an accepted market practice and the requirements for maintaining, withdrawing or amending the conditions for admission, and Articles L. 225-209 et seq. of the French Commercial Code, and the AMF decision no. 2018-01 of July 2, 2018, applicable as of January 1, 2019.
The following resources have been allocated to the liquidity account:
The execution of the Agreement will be suspended under the conditions described in Article 5 of AMF decision no. 2018-01 of July 2, 2018.
The execution of the Agreement may also be suspended:
The Agreement may be terminated:
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2020, the company employed more than 7,500 people, and earned sales revenue of 1,910 million euros.
Head of Investor Relations
Sartorius Stedim Biotech S.A.
Z.I. Les Paluds
Avenue de Jouques, CS 91051
13781 Aubagne Cedex, France
Regulatory filing PDF file
File: Implementation of a new contract of liquidity with Kepler Cheuvreux
|Company:||Sartorius Stedim Biotech SA|
|Avenue de Jouques|
|Phone:||+33 44 284 5600|
|AMF Category:||Share buyback / Disposal of own shares / Information relating to the liquidity contract|
|EQS News ID:||1192368|
|End of Announcement||EQS News Service|
1192368 04-May-2021 CET/CEST